Presentation: 4B05

Cell-based assays have gained widespread application due to their information richness and pharmacological relevance. Performed in high-throughput mode they can be used to generate bioactivity information for complete compound libraries. They provide a well-founded basis for selection of compound classes early in the drug discovery process, reducing the risk of costly late stage failures. The challenge of high-throughput, high-content screening lies in assessing quality and interpreting results.

In our case study a cell-based assay was screened on the EVOscreen® Mark III uHTS system, combined with the high-content confocal imaging system Opera. Analyzed with Genedata Screener® software, the multi-parametric image data is used to systematically discriminate process artifacts from reliable signals and to predict mechanisms of action of active compounds. We show how the integration of high-precision measurement, sophisticated image analysis, automated QC, and statistical analysis generates reliable, detailed activity information on complete libraries and permits an early mechanistic classification of compounds.

Close Window X